GLP-1 RAs, or glucagon-like peptide-1 receptor agonists, are a class of injectable antihyperglycaemic medications used in the management of type 2 diabetes and obesity. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.